Spots Global Cancer Trial Database for metastatic colorectal cancer (mcrc)
Every month we try and update this database with for metastatic colorectal cancer (mcrc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) | NCT05233332 | CRC | HL-085 Vemurafenib | 18 Years - 80 Years | Shanghai Kechow Pharma, Inc. | |
| Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | NCT01705002 | Cancer Solid Tumor Metastatic Colo... | Promitil Capecitabine Bevacizumab | 18 Years - 80 Years | Lipomedix Pharmaceuticals Inc. | |
| Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | NCT02069704 | Metastatic Colo... | Bevacizumab bio... Avastin® (bevac... | 18 Years - | mAbxience Research S.L. | |
| A Study of JMT101 in Patients With Metastatic Colorectal Cancer | NCT06089330 | Metastatic Colo... | JMT101 SG001 Irinotecan Regorafenib (St... | 18 Years - 75 Years | Shanghai JMT-Bio Inc. | |
| Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | NCT02069704 | Metastatic Colo... | Bevacizumab bio... Avastin® (bevac... | 18 Years - | mAbxience Research S.L. | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed | NCT03890731 | Solid Cancer | BAY73-4506 (Reg... | 18 Years - | Bayer | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC) | NCT05420909 | Metastatic Colo... | 18 Years - | Bristol-Myers Squibb | ||
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | NCT04044430 | Metastatic Colo... Metastatic Colo... Metastatic Micr... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... | Binimetinib Encorafenib Nivolumab Questionnaire A... | 18 Years - | University of California, San Francisco | |
| Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | NCT02069704 | Metastatic Colo... | Bevacizumab bio... Avastin® (bevac... | 18 Years - | mAbxience Research S.L. | |
| Phase I/II Combination With Irinotecan- Erbitux | NCT00594984 | Metastatic Colo... | Cetuximab Irinotecan Brivanib Brivanib Brivanib Placeb... | 18 Years - | Bristol-Myers Squibb | |
| A Study of JMT101 in Patients With Metastatic Colorectal Cancer | NCT06089330 | Metastatic Colo... | JMT101 SG001 Irinotecan Regorafenib (St... | 18 Years - 75 Years | Shanghai JMT-Bio Inc. | |
| Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients | NCT03829462 | Metastatic Colo... | Regorafenib Irinotecan | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | NCT04606472 | Solid Tumor | SI-B003 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions | NCT05839951 | Metastatic Colo... | Regorafenib (BA... TAS-102 (triflu... Bevacizumab | 18 Years - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
